OACCFinancial Services · Shell CompaniesOACC Stock Forecast: Oaktree Acquisition Corp. III Life Sciences Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 1 Aug 2026 — in the upper half.
OACC stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Oaktree Acquisition Corp. III Life Sciences on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (92): The share price has been relatively steady.
Growth (16): Sales and profits are flat, shrinking, or growing more slowly than they were.
The rank is the raw material. Whether the rules would actually own Oaktree Acquisition Corp. III Life Sciences — and when they’d sell — is the membership.
OACC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on OACC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
OACC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Oaktree Acquisition Corp. III Life Sciences (OACC) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 37.0×
- Price / sales
- —
- Price / book
- 1.3×
- EV / EBITDA
- −219.8×
Cheaper than 22% of US stocks
Cheaper than 61% of US stocks
Cheaper than 97% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- −16.0%
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 22% of US stocks
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- 3.7%
- Return on assets
- 3.6%
- Dividend yield
- —
Higher than 51% of US stocks
Higher than 69% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
OACC vs competitors
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| OACCOaktree Acquisition Corp. III Life Sciences | $264.0M | 54 |
| VNMEVendome Acquisition Corp. I | $263.9M | 35 |
| TRGSTRG Latin America Acquisitions Corp. | $261.7M | 15 |
| DMAADrugs Made In America Acquisition Corp. | $260.0M | 50 |
| SOULSoulpower Acquisition Corp. | $269.0M | 36 |
| DNMXDynamix Corp. III | $269.3M | 13 |
| JACSJackson Acquisition Co. II | $269.6M | 47 |
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OACC appears on the weeks it earns a place.
Frequently asked questions about OACC stock
How does Ticker Nerd's model rank OACC?
As at 1 Aug 2026, Oaktree Acquisition Corp. III Life Sciences ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (92 of 100).
What is the OACC stock forecast for 2030?
No analyst covering Oaktree Acquisition Corp. III Life Sciences publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OACC are extrapolating price history, which says nothing about the business.
How has OACC stock performed over the past year?
Oaktree Acquisition Corp. III Life Sciences returned +2.6% over the 12 months to 31 July 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Oaktree Acquisition Corp. III Life Sciences do?
Oaktree Acquisition Corp. is a special purpose acquisition company (SPAC) formed for the purpose of executing mergers, share exchanges, asset acquisitions, or similar business combinations with one or more entities.
About Oaktree Acquisition Corp. III Life Sciences.
Oaktree Acquisition Corp. is a special purpose acquisition company (SPAC) formed for the purpose of executing mergers, share exchanges, asset acquisitions, or similar business combinations with one or more entities. Its primary function is to facilitate the transition of private companies into publicly-listed entities without going through the traditional initial public offering (IPO) process. Typically, Oaktree Acquisition Corp. casts a wide net across various industries, enabling it to target diverse sectors that may include technology, healthcare, or consumer products. The company, affiliated with Oaktree Capital Management, utilizes its strategic partnerships and expertise in asset management to identify high-potential companies poised for growth. Oaktree Acquisition Corp. holds a significant position in the financial market by providing an alternative route for businesses to access public capital markets, contributing to the growing trend of SPAC formations and transactions. Its operations reflect a strategic approach to harnessing market opportunities and investor capital, emphasizing transformative potential in its selection of target companies.
CEO Mr. Zaid Pardesi · United States · https://www.oaktreeacquisitioncorp.com/oac-iii